Free Trial Information
BioCentury | Sep 26, 2011
Clinical News

HF1020: Phase Ia started

...ascending-doses of 0.5, 2.5, 10 and 25 mg oral HF1020 in 32 healthy male volunteers. Trident Pharmaceuticals Inc....
Read More
BioCentury | Feb 18, 2008
Strategy

For want of a horse. . .

...that is in discovery as a neuroprotectant. Newron also will receive Hunter-Fleming's 17% stake in Trident Pharmaceuticals Inc....
...Ltd. , Bristol, U.K. Merck KGaA (FSE:MRK), Darmstadt, Germany Newron Pharmaceuticals S.p.A. (SWX:NWRN), Bresso, Italy Trident Pharmaceuticals Inc....
Read More
BioCentury | Feb 18, 2008
Company News

Hunter-Fleming, Newron deal

...HF0299 , a steroid to treat neuropathic pain. Newron will receive Hunter-Fleming’s 17% stake in Trident Pharmaceuticals Inc....
Read More
BioCentury | May 7, 2007
Finance

Global visibility

...and agreed with Omega to invest $15 million in a special purpose vehicle called Trident Pharmaceuticals...
Read More
BioCentury | Apr 10, 2006
Company News

Trident board of directors update

Trident Pharmaceuticals Inc. , Boston, Mass. Business: Inflammation Appointed: James Murray, CEO of Hunter-Fleming Ltd. , as chairman WIR Staff Inflammation...
Read More
BioCentury | Apr 10, 2006
Company News

Trident management update

Trident Pharmaceuticals Inc. , Boston, Mass. Business: Inflammation Hired: Marios Fotiadis, a venture partner at Advent International, as acting CEO; and Robin Brown, a venture partner at Advent, as CSO WIR Staff Inflammation...
Read More
BioCentury | Apr 3, 2006
Finance

Ebb & Flow

...million series B round plus an additional $15 million in a separate financing to establish Trident Pharmaceuticals...
Read More
Items per page:
1 - 7 of 7
BioCentury | Sep 26, 2011
Clinical News

HF1020: Phase Ia started

...ascending-doses of 0.5, 2.5, 10 and 25 mg oral HF1020 in 32 healthy male volunteers. Trident Pharmaceuticals Inc....
Read More
BioCentury | Feb 18, 2008
Strategy

For want of a horse. . .

...that is in discovery as a neuroprotectant. Newron also will receive Hunter-Fleming's 17% stake in Trident Pharmaceuticals Inc....
...Ltd. , Bristol, U.K. Merck KGaA (FSE:MRK), Darmstadt, Germany Newron Pharmaceuticals S.p.A. (SWX:NWRN), Bresso, Italy Trident Pharmaceuticals Inc....
Read More
BioCentury | Feb 18, 2008
Company News

Hunter-Fleming, Newron deal

...HF0299 , a steroid to treat neuropathic pain. Newron will receive Hunter-Fleming’s 17% stake in Trident Pharmaceuticals Inc....
Read More
BioCentury | May 7, 2007
Finance

Global visibility

...and agreed with Omega to invest $15 million in a special purpose vehicle called Trident Pharmaceuticals...
Read More
BioCentury | Apr 10, 2006
Company News

Trident board of directors update

Trident Pharmaceuticals Inc. , Boston, Mass. Business: Inflammation Appointed: James Murray, CEO of Hunter-Fleming Ltd. , as chairman WIR Staff Inflammation...
Read More
BioCentury | Apr 10, 2006
Company News

Trident management update

Trident Pharmaceuticals Inc. , Boston, Mass. Business: Inflammation Hired: Marios Fotiadis, a venture partner at Advent International, as acting CEO; and Robin Brown, a venture partner at Advent, as CSO WIR Staff Inflammation...
Read More
BioCentury | Apr 3, 2006
Finance

Ebb & Flow

...million series B round plus an additional $15 million in a separate financing to establish Trident Pharmaceuticals...
Read More
Items per page:
1 - 7 of 7